a systematic analysis for the Global Burden of Disease Study 2016. GBD 2016 Parkinson's Disease Collaborators, Lancet Neurol, vol.17, issue.18, pp.30295-30298, 1990. ,
NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease, Mov Disord, vol.26, pp.399-406, 2011. ,
Determinants of health-related quality of life in Parkinson's disease: A systematic review, Parkinsonism Relat Disord, vol.17, pp.1-9, 2011. ,
Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients, Eur J Neurol, vol.21, pp.519-524, 2014. ,
Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson's disease, J Neurol Sci, vol.373, pp.173-178, 2017. ,
Determinants of generic and specific health-related quality of life in patients with Parkinson's disease, PLoS One, vol.12, p.178896, 2017. ,
An introduction to the concept of "quality of life in Parkinson's disease, J Neurol, vol.245, issue.1, pp.2-6, 1998. ,
International use, application and performance of health-related quality of life instruments, Qual Life Res, vol.2, pp.367-368, 1993. ,
Quality of life in health care: Concepts and components, pp.1-15, 1999. ,
, Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products, European Medicines Agency, 2005.
Guidance for Industry Patient-Reported Outcome Measures: Use in medical product development to support labeling claims. U.S. Department of Health and Human Services Food and Drug Administration, 2009. ,
Health-related quality-of-life scales in Parkinson's disease: critique and recommendations, Mov Disord, vol.26, pp.2371-2380, 2011. ,
Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study, Parkinsonism Relat Disord, vol.19, pp.56-61, 2013. ,
Neurostimulation for Parkinson's disease with early motor complications, N Engl J Med, vol.368, pp.610-622, 2013. ,
Neurostimulation for Parkinson's disease with early motor complications, N Engl J Med, vol.368, p.2038, 2013. ,
Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EAR-LYSTIM trial): secondary analysis of an open-label randomised trial, Lancet Neurol, vol.17, pp.223-231, 2018. ,
Quality of life predicts outcome of deep brain stimulation in early Parkinson disease, Neurology, vol.92, issue.10, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02373051
Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease: the EARLYSTIM trial: early is not always better, Mov Disord, vol.29, pp.1751-1756, 2014. ,
Are Patients Ready for "EARLYSTIM"? Attitudes towards Deep Brain Stimulation among Female and Male Patients with Moderately Advanced Parkinson's Disease, Parkinsons Dis, 2017. ,
Critical appraisal of the recent US FDA approval for earlier DBS intervention, Neurology, vol.91, pp.133-136, 2018. ,
A point of minimal important difference (MID): a critique of terminology and methods, Expert Rev Pharmacoecon Outc Res, vol.11, pp.171-184, 2011. ,
Capturing the patient's view of change as a clinical outcome measure, JAMA, vol.282, issue.12, pp.1157-62, 1999. ,
The Clinical Global Impression Scale and the influence of patient or staff perspective on outcome, BMC Psychiatry, vol.11, p.83, 2011. ,
Measurement of health status. Ascertaining the minimal clinically important difference, Contr Clin Trials, vol.10, pp.407-415, 1989. ,
Defining clinically meaningful change in health-related quality of life, J Clin Epidemiol, vol.56, pp.44-45, 2003. ,
Methods for interpreting change over time in patientreported outcome measures, Industry Advisory Committee of International Society for Quality of Life Research (ISOQOL), vol.22, pp.475-483, 2013. ,
Interpretation of changes in health-related quality of life: the remarkable universality of a half a standard deviation, Med Care, vol.41, pp.582-592, 2003. ,
Clinical significance of patient-reported questionnaire data: another step toward consensus, J Clin Epidemiol, vol.58, pp.1217-1219, 2005. ,
Research Methods in Health: Investigating Health and Health Services Research, p.202, 2002. ,
Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes, J Clin Epidemiol, vol.61, pp.102-109, 2008. ,
Relation of distribution-and anchor-based approaches in interpretation of changes in health-related quality of life, Med Care, vol.39, pp.1039-1086, 2001. ,
Estimating clinically significant differences in quality of life outcomes, Qual Life Res, vol.14, pp.285-295, 2005. ,
Minimal changes in health status questionnaires: distinction between minimally detectable change and minimally important change, Health Qual Life Outcomes, vol.4, p.54, 2006. ,
The minimal detectable change cannot reliably replace the minimal important difference, J Clin Epidemiol, vol.63, issue.1, pp.28-36, 2010. ,
Health-related quality of life as an outcome variable in Parkinson's disease, Ther Adv Neurol Disord, vol.5, issue.2, pp.105-122, 2012. ,
Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire, Age Ageing, vol.30, issue.4, pp.299-302, 2001. ,
When to use agreement versus reliability measures, J Clin Epidemiol, vol.59, issue.10, pp.1033-1042, 2006. ,
Longitudinal psychometric attributes, responsiveness, and importance of change: An approach using the SCOPA-Psychosocial questionnaire, Mov Disord, vol.23, issue.11, pp.1516-1539, 2008. ,
Changes in quality of life in Parkinson's disease: How large must they be to be relevant?, Neuroepidemiology, vol.48, issue.1-2, pp.1-8, 2017. ,
Measuring quality of life in palliative care for Parkinson's disease: A clinimetric comparison, Parkinsonism Relat Disord, vol.65, pp.172-177, 2019. ,
Perceptions of symptoms and expectations of advanced therapy for Parkinson's disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson's disease (PRO-APD). Health Qual Life Outcomes, vol.12, p.11, 2014. ,
Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease, Mov Disord, vol.22, issue.6, pp.757-65, 2007. ,
Cuánto ha mejorado la calidad de vida de los pacientes con enfermedad de Parkinson?, Rev Esp Trast Mov, vol.6, pp.14-21, 2014. ,
Impact of pharmacotherapy on quality of life in patients with Parkinson's disease, CNS Drugs, vol.29, issue.5, p.25968563, 2015. ,
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes, Mov Disord, vol.21, pp.290-304, 2006. ,
A review of health-related quality-of-life concepts and measures for Parkinson's disease, Qual Life Res, vol.8, issue.3, pp.235-278 ,
What contributes to quality of life in patients with Parkinson's disease?, J Neurol Neurosurg Psychiatry, vol.69, issue.3, pp.308-320, 2000. ,
Determinants of quality of life in Brazilian patients with Parkinson's disease, Mov Disord, vol.22, issue.10, pp.1408-1423, 2007. ,
Determinants of health-related quality of life in people with Parkinson's disease: a path analysis, Qual Life Res, vol.22, issue.7, p.23070750, 2013. ,
Determinants of the quality of life in Parkinson's disease: results of a cohort study from Southwest China, J Neurol Sci, vol.15, issue.1-2, pp.144-153, 2014. ,